CLASS ACTION UPDATE for RCL, ZSAN and ICPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
RCL Shareholders Click Here: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10900&wire=1
ZSAN Shareholders Click Here: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=10900&wire=1
ICPT Shareholders Click Here: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=10900&wire=1
* ADDITIONAL INFORMATION BELOW *
Royal Caribbean Cruises Ltd. (NYSE:RCL)
RCL Lawsuit on behalf of: investors who purchased February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline : December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/royal-caribbean-cruises-ltd-loss-submission-form?prid=10900&wire=1
According to the filed complaint, during the class period, Royal Caribbean Cruises Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
Zosano Pharma Corporation (NASDAQ:ZSAN)
ZSAN Lawsuit on behalf of: investors who purchased February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline : December 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=10900&wire=1
According to the filed complaint, during the class period, Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
ICPT Lawsuit on behalf of: investors who purchased September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline : January 4, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?prid=10900&wire=1
According to the filed complaint, during the class period, Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/616407/CLASS-ACTION-UPDATE-for-RCL-ZSAN-and-ICPT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
